Literature DB >> 7893992

Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions.

A A Eddy.   

Abstract

Although chronic progressive tubulointerstitial (TI) disease plays a critical role in the outcome of patients with primary glomerular lesions, the basic mechanisms that generate the TI damage remain unclear. This review focuses on recent insights into this process that originate primarily from studies of animal models of glomerular injury. The acute phase, which is often clinically silent, is characterized by tubular epithelial cell injury and interstitial inflammation. Proposed mediators of tubular injury include antibodies, lysosomal enzymes, obstruction, reactive oxygen metabolites, and complement. Damaged tubules may regenerate or undergo necrosis or apoptosis. The identification of the molecular mediators of mononuclear cell recruitment to the interstitium is of current interest because of evidence that monocytes/macrophages play a key role in progressive interstitial scarring through the release of fibrosis-promoting cytokines, particularly transforming growth factor-beta 1 (TGF-beta 1). Events linked to the initiation of interstitial inflammation include the deposition of antibodies or immune complexes along the tubular basement membranes, T cell-dependent mechanisms, glomerular factors, and factors linked to proteinuria. Several molecules likely regulate the interstitial migration of circulating monocytes, although the critical mediators are presently unknown. Candidates include chemotactic factors such as intercrines, growth factors, complement, lipid factors, osteopontin, and monocyte adhesion molecules (beta 1 integrins, beta 2 integrins, and L-selectins). The hallmark of the chronic phase of TI damage is interstitial fibrosis. Of the several candidate fibrogenic cytokines, to date, only TGF-beta 1 has been studied in any detail. TGF-beta 1 is produced by interstitial inflammatory cells and appears to trigger increased matrix production by perivascular and interstitial fibroblasts. Awaiting clarification is the role of tubular cells in vivo as a source of fibrogenic cytokines or as a site of increased matrix synthesis, activities they do perform in vitro. Preliminary studies suggest that interstitial fibrosis may also be due in part to the failure of matrix degradation by metalloproteinases and plasmin as a result of the overexpression of the enzyme inhibitors. The existence of an intrarenal matrix-degrading enzyme cascade suggests that renal fibrosis may be reversible, at least to a limited extent. In summary, during the early stage of glomerular injury, numerous cellular and molecular mediators of acute interstitial disease are activated and ultimately converge on common pathways that lead to progressive renal scarring.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893992     DOI: 10.1681/ASN.V561273

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

1.  Signficance of tubulointerstitial lesions in kidney biopsy specimen of nephrotic patients in Iraq.

Authors:  Abbas Ali Mansour; Ihsan Al-Shamma
Journal:  MedGenMed       Date:  2006-01-10

2.  Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury.

Authors:  Beom Jin Lim; Jae Won Yang; Jun Zou; Jianyong Zhong; Taiji Matsusaka; Ira Pastan; Ming-Zhi Zhang; Raymond C Harris; Hai-Chun Yang; Agnes B Fogo
Journal:  Kidney Int       Date:  2017-07-12       Impact factor: 10.612

3.  Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist.

Authors:  A Benigni; E Gagliardini; A Remuzzi; D Corna; G Remuzzi
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis.

Authors:  R E Gilbert; L L Wu; D J Kelly; A Cox; J L Wilkinson-Berka; C I Johnston; M E Cooper
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

5.  Hepatocyte Growth Factor-Secreting Mesothelial Cell Sheets Suppress Progressive Fibrosis in a Rat Model of CKD.

Authors:  Masatoshi Oka; Sachiko Sekiya; Ryoichi Sakiyama; Tatsuya Shimizu; Kosaku Nitta
Journal:  J Am Soc Nephrol       Date:  2019-01-11       Impact factor: 10.121

6.  Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases.

Authors:  R Konda; H Sato; K Sakai; M Sato; S Orikasa; N Kimura
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

7.  Early detection of chronic kidney disease: results of the PolNef study.

Authors:  Ewa Król; Bolesław Rutkowski; Piotr Czarniak; Ewa Kraszewska; Sławomir Lizakowski; Radosław Szubert; Stanisław Czekalski; Władysław Sułowicz; Andrzej Wiecek
Journal:  Am J Nephrol       Date:  2008-09-23       Impact factor: 3.754

8.  Expression of JAKs/STATs pathway molecules in rat model of rapid focal segmental glomerulosclerosis.

Authors:  Yaojun Liang; Yu Jin; Yuning Li
Journal:  Pediatr Nephrol       Date:  2009-04-07       Impact factor: 3.714

9.  Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.

Authors:  Atsuko Kamijo; Takeshi Sugaya; Akihisa Hikawa; Mitsuhiro Okada; Fumikazu Okumura; Masaya Yamanouchi; Akiko Honda; Masaru Okabe; Tomoya Fujino; Yasunobu Hirata; Masao Omata; Ritsuko Kaneko; Hiroshi Fujii; Akiyoshi Fukamizu; Kenjiro Kimura
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

10.  PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.

Authors:  Jee-Young Han; Ye-Ji Kim; Lucia Kim; Suk-Jin Choi; In-Suh Park; Joon-Mee Kim; Young Chae Chu; Dae-Ryong Cha
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.